How has the medical linear particle accelerator market evolved, and where is it heading next?
The medical linear particle accelerator market size has grown strongly in recent years. It will grow from $2.55 billion in 2024 to $2.69 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to increased access to healthcare, increasing demand for radiotherapy infrastructure, demand for proton therapy, increase in multimodal cancer treatments and increased adoption of robotic-assisted surgeries.
The medical linear particle accelerator market size is expected to see strong growth in the next few years. It will grow to $3.31 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to growing demand for personalized medicine, growing adoption of low-cost radiation therapy solutions, increasing clinical trials, rising demand for minimally invasive surgery and rising adoption of targeted cancer therapies. Major trends in the forecast period include technological advancements in radiation therapy, telemedicine and remote radiotherapy planning, integration of artificial intelligence (AI) and machine learning (ML), advancements in imaging modalities and integration of radiotherapy with digital health technologies.
Get Your Free Sample of The Global Medical Linear Particle Accelerator Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20872&type=smp
What are the key drivers behind the rapid expansion of the medical linear particle accelerator market?
The growing incidence of cancer is expected to propel the growth of the medical linear particle accelerator market going forward. Cancer refers to a group of diseases where abnormal cells grow uncontrollably and spread, often forming tumors or affecting other parts of the body. The growing incidence of cancer can be attributed to factors such as environmental exposures, genetic predisposition, improved detection and screening, infections, hormonal factors, and increased awareness. Medical linear particle accelerators (LINACs) help in cancer treatment by delivering precise high-energy radiation to target and destroy cancer cells, enhancing treatment effectiveness and reducing side effects. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in Australia the number of cancer cases diagnosed increased from 160,570 in 2022 to 164,694 in 2023, reflecting a notable rise over the year. Therefore, the growing incidence of cancer is driving the growth of the medical linear particle accelerator market.
What is the segmentation for the medical linear particle accelerator market?
The medical linear particle accelerator market covered in this report is segmented –
1) By Product Type: Dedicated Linear Accelerator, Non-Dedicated Linear Accelerator
2) By Treatment Type: Intensity Modulated Radiation Therapy, Volumetric Modulated Arc Therapy, Image Guided Radiation Therapy, Stereotactic Radiosurgery And Stereotactic Body Radiotherapy
3) By End-User: Hospital, Radiology, Clinics, Other End-Users
Subsegments:
1) By Dedicated Linear Accelerator: Radiation Therapy Linear Accelerators, Medical Linear Accelerators for Cancer Treatment, High-Energy Linear Accelerators
2) By Non-Dedicated Linear Accelerator: General Purpose Linear Accelerators, Laboratory-Grade Non-Dedicated Linear Accelerators, Research And Development Linear Accelerators
Order your report now for swift delivery
Who are the most influential companies in the medical linear particle accelerator market?
Major companies operating in the medical linear particle accelerator market are Mitsubishi Electric Corporation, Siemens Healthineers AG, Toshiba Medical Systems Corporation, GE Healthcare, Shinva Medical Instrument Co Ltd, Sumitomo Heavy Industries Ltd, Neusoft Medical Systems Co Ltd, Elekta AB, Varex Imaging Corporation, Altair Engineering Inc, Accuray Incorporated, Brainlab, Nordion Inc., Ion Beam Applications S.A. (IBA), Hitachi Medical Corporation, ViewRay Technologies Inc., Laird Thermal Systems Inc., Panacea Medical Technologies Pvt Ltd, RadSource Technologies Inc., Xstrahl Limited, MedicalExpo S.A, ProTom International Inc., ASG superconductors, Galbino Technology Inc., Mevex Corporation, TibaRay Inc.
What are the most influential trends expected to drive the medical linear particle accelerator market forward?
Major companies operating in the medical linear particle accelerator market are focusing on developing technologically advanced solutions, such as radiotherapy systems, to enhance treatment precision and improve patient outcomes in cancer therapy. Radiotherapy systems refer to medical technologies, such as linear accelerators, that use high-energy radiation to precisely target and treat tumors while minimizing damage to surrounding healthy tissue. For instance, in May 2024, Elekta AB, a Sweden-based medical equipment company, launched Elekta Evo, an AI-powered adaptive CT-linear accelerator aimed at transforming cancer care. Equipped with Iris, a high-definition AI-enhanced imaging system, Elekta Evo enables clinicians to visualize treatment areas with remarkable clarity, ensuring precise tumor targeting while protecting surrounding healthy tissue. The device also incorporates adaptive radiation therapy capabilities, allowing for both online and offline adjustments to treatment plans, thus personalizing care to meet each patient’s unique needs.
What are the major regional insights for the medical linear particle accelerator market, and which region holds the top position?
North America was the largest region in the medical linear particle accelerator market in 2024. The regions covered in the medical linear particle accelerator market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Medical Linear Particle Accelerator Market Report 2025 Offer?
The medical linear particle accelerator market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
A medical linear particle accelerator (LINAC) is a device used in radiation therapy to treat cancer by delivering high-energy X-rays or electron beams to target tumors with precision while minimizing damage to surrounding healthy tissue. It accelerates electrons using microwave technology, producing radiation beams that conform to the tumor’s shape for effective treatment.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20872
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
